Tu Diep

Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.

Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc., (now Sophiris Bio Inc.), a company developing highly targeted, minimally invasive treatment for benign prostatic hyperplasia and prostate cancer. While at Protox, Mr. Diep held several positions with increasing responsibility where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. Prior to leaving Protox, he was integrally involved in solidifying a $75 million regional partnership with a Japanese pharmaceutical company, as well as, securing a $35 million investment from the private equity firm, Warburg Pincus.

In 2011, Mr. Diep joined OncoSec Medical Inc. as a founding employee. He led the development and initiation of the Company’s lead program, tavokinogene telsaplasmid (TAVO), an intratumoral gene therapy using DNA plasmid-encoding interleukin-12. As a key member of OncoSec’s executive management team, he spearheaded a key clinical collaboration with Merck to evaluate the combination of TAVO plus pembrolizumab, Merck’s leading anti-PD-1 antibody for the treatment of metastatic melanoma.

Following OncoSec, Mr. Diep held positions as VP, Strategic Operations for a global cannabis company, Emerald Health Sciences, and in addition, held the role of Director, Business Process for a private next-generation sequencing start-up, Element Biosciences. Mr. Diep holds a Master of Science in Physiology from the University of Toronto.